만성 폐쇄성 폐질환(COPD) 및 천식용 의료기기 시장 보고서 : 제품, 적응증, 유통 채널 및 지역별(2024-2032년)

The global COPD and asthma devices market size reached US$ 45.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 69.5 Billion by 2032, exhibiting a growth rate (CAGR) of 4.6% during 2024-2032.

Chronic obstructive pulmonary disease (COPD) is an inflammatory disease that leads to obstructed airflow from the lungs. Its early symptoms include shortness of breath, wheezing, chest tightness, chronic cough with or without mucus, frequent cold, and throat soreness. On the other hand, asthma, also known as bronchial asthma, is a respiratory disorder that affects the airways in the lungs. Its symptoms are shortness of breath, chest tightness, trouble sleeping, and coughing or wheezing attacks. These respiratory diseases are treated using various devices that help deliver inhaled medication. COPD and asthma devices, also known as pulmonary drug delivery devices, are used as permanent treatment or rescue therapy for respiratory diseases. As a result, they are gaining immense traction across the globe.

COPD and Asthma Devices Market Trends:

The growing global geriatric population, which is highly susceptible to chronic respiratory disorders, represents one of the key factors positively influencing the market. In addition, rising occurrences of respiratory diseases caused due to the rising smoking of cigarettes are increasing the sales of COPD and asthma devices. Apart from this, the increasing expenditure on healthcare and continuous automation in the healthcare industry are contributing to the market growth. The widespread adoption of advanced medical solutions is offering lucrative growth opportunities to manufacturers across the globe. At present, healthcare practitioners and pulmonary diseases specialists are preferring a combination of a drug and a device on account of their fast and effective outcome. Furthermore, the expansion of chemical industries is resulting in the rising environmental pollution level and breathing problems, which, in turn, is driving the market. Additionally, the introduction of portable drug delivery devices is propelling the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global COPD and asthma devices market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, indication and distribution channel.

Breakup by Product:

Inhalers

Drug Powdered Inhalers (DPIs)

Metered Dose Inhalers (MDIs)

Soft Mist Inhalers

Nebulizers

Compressor Nebulizers

Ultrasonic Nebulizers

Mesh Nebulizers

Breakup by Indication:

Asthma

COPD

Breakup by Distribution Channel:

Retail Pharmacies

Hospitals

Online Pharmacies

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Adherium Limited, Aristopharma Ltd., AstraZeneca PLC, Baxter International Inc., Boehringer Ingelheim International GmbH, Cohero Health Inc., Koninklijke Philips N.V., Omron Corporation, Pari Respiratory Equipment Inc., Recipharm AB and Verona Pharma plc.

Key Questions Answered in This Report

• 1. What was the size of the global COPD and asthma devices market in 2023?
• 2. What is the expected growth rate of the global COPD and asthma devices market during 2024-2032?
• 3. What are the key factors driving the global COPD and asthma devices market?
• 4. What has been the impact of COVID-19 on the global COPD and asthma devices market?
• 5. What is the breakup of the global COPD and asthma devices market based on the product?
• 6. What is the breakup of the global COPD and asthma devices market based on the indication?
• 7. What is the breakup of the global COPD and asthma devices market based on distribution channel?
• 8. What are the key regions in the global COPD and asthma devices market?
• 9. Who are the key players/companies in the global COPD and asthma devices market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global COPD and Asthma Devices Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Inhalers
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Drug Powdered Inhalers (DPIs)
    • 6.1.2.2 Metered Dose Inhalers (MDIs)
    • 6.1.2.3 Soft Mist Inhalers
  • 6.1.3 Market Forecast
• 6.2 Nebulizers
  • 6.2.1 Market Trends
  • 6.2.2 Key Segments
    • 6.2.2.1 Compressor Nebulizers
    • 6.2.2.2 Ultrasonic Nebulizers
    • 6.2.2.3 Mesh Nebulizers
  • 6.2.3 Market Forecast

7 Market Breakup by Indication

• 7.1 Asthma
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 COPD
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

• 8.1 Retail Pharmacies
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Hospitals
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Online Pharmacies
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Adherium Limited
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
  • 14.3.2 Aristopharma Ltd.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 AstraZeneca PLC
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Baxter International Inc.
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Boehringer Ingelheim International GmbH
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
  • 14.3.6 Cohero Health Inc.
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
  • 14.3.7 Koninklijke Philips N.V.
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Omron Corporation
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Pari Respiratory Equipment Inc.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
  • 14.3.10 Recipharm AB
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
  • 14.3.11 Verona Pharma plc
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
    • 14.3.11.4 SWOT Analysis